Business Context and Reporting Period
Company: NeoGenomics, Inc. (NEO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: NeoGenomics operates a network of cancer-focused testing laboratories in the U.S. and U.K., providing oncology diagnostic testing, molecular and NGS testing, and pharmaceutical development services. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $186,672 | $168,035 |
| Gross Profit | $80,864 | $73,246 |
| Gross Margin | 43.3% | 43.6% |
| Operating Loss | $(18,241) | $(27,825) |
| Net Loss | $(17,106) | $(25,923) |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.20) |
| Adjusted EBITDA (Non-GAAP) | $9,004 | $7,070 |
| Cash and Cash Equivalents (End of Period) | $146,143 | $346,194 |
| Working Capital | $289,094 | $294,237 |
| Convertible Senior Notes (Net Carrying Value) | $342,240 | $341,858 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 11.1% ($18.6 million) driven by higher test volumes, a shift to higher-value tests, and the contribution from the Pathline acquisition. This was partially offset by lower non-clinical revenue due to macro trends in the pharmaceutical industry.
- Cost of Revenue: Increased 11.6% primarily due to a $5.3 million rise in supplies expense and $5.0 million in higher compensation costs. Gross margin decreased slightly by 0.3%.
- Operating Expenses: General and administrative expenses decreased 3.6% ($2.5 million) due to a $4.3 million reduction in non-recurring legal and transaction costs. Sales and marketing expenses increased 5.1% due to sales force expansion.
- Interest Expense: Decreased 63.0% to $0.6 million following the maturity and settlement of the 2025 Convertible Notes in May 2025.
- Cash Flow: Net cash used in operating activities improved significantly to $8.1 million from $25.3 million in the prior year, driven by improved gross profit and changes in working capital.
Guidance, Outlook, and Risks
- Capital Expenditures: Management forecasts capital expenditures for the full year 2026 to be in the range of $30.0 million to $35.0 million.
- Liquidity: The company holds $146.1 million in unrestricted cash and expects sufficient liquidity to fund operations for at least the next 12 months.
- Strategic Focus: 2026 priorities include targeted product launches in therapy selection and Molecular Residual Disease (MRD), expanding the community oncology market, and optimizing operational efficiency through automation.
- Regulatory Risks: The company faces ongoing uncertainty regarding FDA regulation of Laboratory Developed Tests (LDTs). While a recent court decision vacated a final rule, future legislative or administrative actions could increase compliance costs.
- Legal Contingencies: The company has accrued a $11.2 million reserve for potential damages related to an internal investigation into federal healthcare compliance. A shareholder class action (Goldenberg Matter) was dismissed with prejudice in March 2026 but has been appealed by the plaintiff.
Investor Verification Checklist
- Regulatory Reserve: Verify the sufficiency of the $11.2 million reserve for the ongoing federal healthcare compliance investigation and potential future accruals.
- Pharma Revenue Exposure: Assess the impact of macro clinical trial trends on non-clinical revenue streams, which offset some growth in the quarter.
- Debt Conversion Risk: Monitor the stock price relative to the conversion price of the 2028 Convertible Notes ($85.75) to evaluate potential dilution or conversion triggers.
- Working Capital Trends: Review the increase in accounts receivable ($8.2 million increase in cash used) to ensure collection efficiency remains stable.
- Legal Appeals: Track the status of the appeal regarding the dismissed Goldenberg shareholder class action.